logo
ENTITY

Cadrenal Therapeutics (CVKD US)

3
Analysis
Health Care • United States
Cadrenal Therapeutics, Inc. operates as a biotech company. The Company focuses on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation. Cadrenal Therapeutics serves customers worldwide.
more
bullish•Cadrenal Therapeutics
•21 Nov 2024 03:00•Issuer-paid

CVKD: Recent Financings Raise 9.8 Million

On November 7, 2024, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the third quarter of 2024 and provided a business...

Logo
Share
bullish•Cadrenal Therapeutics
•27 Sep 2024 01:00•Issuer-paid

CVKD: New Blood Thinner Ready for Phase 3 Initiating Coverage of Cadrenal Therapeutics Inc

We are initiating coverage of Cadrenal Therapeutics, Inc. (CVKD) with a valuation of $30.00. Cadrenal is a clinical stage biopharmaceutical...

Logo
Share
bullish•Cadrenal Therapeutics
•16 Sep 2024 22:00•Issuer-paid

Cadrenal Therapeutics Inc - September 16, 2024

We are initiating coverage of Cadrenal Therapeutics, Inc. (CVKD) with a valuation of $30.00. Cadrenal is a clinical stage biopharmaceutical...

Logo
Share
No more insights

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x